A recent article by Tristan César Mañalac in BioSpace spotlights six startups that are redefining how the biotech sector approaches aging. The article outlines how the field is shifting from speculative longevity claims to clinical strategies grounded in clear mechanisms and disease relevance.
We’re proud to see two companies closely tied to LongeVC featured. Rubedo Life Sciences, one of our portfolio companies, is recognized for its work on senolytics with a disease-agnostic, mechanism-first approach. Insilico Medicine, led by LongeVC advisory board chair Alex Zhavoronkov, continues to push the boundaries of AI-enabled drug discovery.
The article also highlights Altos Labs, BioAge Labs, Halia Therapeutics, and Life Biosciences as part of this new wave of translational longevity science.
Read the full article here.
We’re proud to see two companies closely tied to LongeVC featured. Rubedo Life Sciences, one of our portfolio companies, is recognized for its work on senolytics with a disease-agnostic, mechanism-first approach. Insilico Medicine, led by LongeVC advisory board chair Alex Zhavoronkov, continues to push the boundaries of AI-enabled drug discovery.
The article also highlights Altos Labs, BioAge Labs, Halia Therapeutics, and Life Biosciences as part of this new wave of translational longevity science.
Read the full article here.